A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Microbot Medical Inc.
MBOT
$10M
Mkt Cap
$1.71
-2.84%
Microbot Medical Inc. (MBOT) has a 5-year average return on invested capital (ROIC) of -34.1%. This is below average and may indicate limited pricing power.
Microbot Medical Inc. (MBOT) has a market capitalization of $115M. It is classified as a small-cap stock.
Microbot Medical Inc. (MBOT) does not currently pay a regular dividend.
Microbot Medical Inc. (MBOT) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
Microbot Medical Inc. (MBOT) generated $5 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Microbot Medical Inc. (MBOT) has a debt-to-equity ratio of 3.58. This indicates higher leverage, which may increase financial risk.
Microbot Medical Inc. (MBOT) reported earnings per share (EPS) of $1.16 in its most recent fiscal year.
Item 1. Description of Business. Microbot is a clinical-stage medical device company specializing in the research, design and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. We are primarily focused on leveraging our robotic technologies with the goal of redefining surgical robotics while improving surgical outcomes for patients. Using our LIBERTY® technological platform, we are developing the first ever fully disposable robot for various endovascular interventional procedures. The LIBERTY® Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It is intended for the remote delivery and manipulation of guidewires and catheters, and remote manipulation of guide catheters to facilitate navigation to anatomical targets, with the current intention to focus in the peripheral vasculature market.
| Metric | TTM | FY2018 | FY2017 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | - | 0 | - |
| Net Income | -13M | 7.0M | 6.0M | 561K | -33M | -26M |
| EPS | $-0.27 | $1.16 | $22.38 | $3.00 | $-39.75 | $-45.75 |
| Free Cash Flow | -13M | 5.1M | 4.8M | 763K | -28M | -28M |
| ROIC | -14.3% | -447.3% | 40.4% | 12.6% | -482.0% | -155.2% |
| Gross Margin | - | 0.0% | 0.0% | - | 0.0% | - |
| Debt/Equity | 0.00 | 3.58 | 0.06 | -78.13 | 5.83 | 0.34 |
| Dividends/Share | $0.00 | $0.00 | $0.00 | - | $0.00 | - |
| Operating Income | -15M | -7.2M | 5.3M | 915K | -31M | -28M |
| Operating Margin | 0.0% | 0.0% | 0.0% | - | 0.0% | - |
| ROE | -16.9% | 123.8% | 102.8% | 141.5% | -414.2% | -182.7% |
| Shares Outstanding | 67M | 6M | 0M | 0M | 1M | 1M |
| Metric | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 0 | N/A | N/A | N/A | N/A | 0 | N/A | 0 | 0 | 0 |
| Gross Margin | 0.0% | N/A | N/A | N/A | N/A | 0.0% | N/A | 0.0% | 0.0% | N/A |
| R&D | 20M | 21M | 20M | 15M | 19M | 22M | -823K | 1.1M | 2.5M | 6.3M |
| SG&A | 9.5M | 9.4M | 8.2M | 7.4M | 8.8M | 10M | -92K | 4.2M | 4.7M | 8.5M |
| EBIT | -29M | -29M | -28M | -22M | -28M | -31M | 915K | 5.3M | -7.2M | -15M |
| Op. Margin | 0.0% | N/A | N/A | N/A | N/A | 0.0% | N/A | 0.0% | 0.0% | 0.0% |
| Net Income | -27M | -25M | -21M | -28M | -26M | -33M | 561K | 6.0M | 7.0M | -13M |
| Net Margin | 0.0% | N/A | N/A | N/A | N/A | 0.0% | N/A | 0.0% | 0.0% | 0.0% |
| Non-Recurring | 0 | 73K | -32K | -21K | 39K | 1.9M | 408K | 0 | 0 | 0 |
| Returns on Capital | ||||||||||
| ROIC | N/A | -108.2% | -157.6% | -57.4% | -155.2% | N/M | 12.6% | 40.4% | N/M | -14.3% |
| ROE | N/A | -109.8% | -162.8% | -230.6% | -182.7% | -414.2% | 141.5% | 102.8% | 123.8% | -16.9% |
| ROA | -6192.7% | -162.7% | -76.4% | -102.9% | -73.7% | -88.5% | 3.4% | 83.5% | 81.9% | -16.1% |
| Cash Flow | ||||||||||
| Op. Cash Flow | -25M | -25M | -22M | -20M | -23M | -27M | 765K | 4.9M | 5.3M | -13M |
| Free Cash Flow | -25M | -25M | -22M | -20M | -28M | -28M | 763K | 4.8M | 5.1M | -13M |
| Owner Earnings | -31M | -30M | -27M | -24M | -27M | -31M | -4.6M | 4.4M | 3.9M | -14M |
| CapEx | 701K | 924K | 297K | 73K | 4.7M | 904K | 2K | 58K | 223K | 60K |
| Maint. CapEx | 1.7M | 1.5M | 1.2M | 992K | 1.1M | 1.3M | 1.1M | 21K | 54K | 47K |
| Growth CapEx | 0 | 0 | 0 | 0 | 3.6M | 0 | 0 | 37K | 169K | 13K |
| D&A | 1.7M | 1.5M | 1.2M | 992K | 1.1M | 1.3M | 1.1M | 21K | 54K | 47K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | N/A | N/A | N/A | N/A | 0.0% | N/A | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | 4.2M | 3.9M | 3.3M | 2.9M | 2.6M | 2.0M | 4.2M | 479K | 1.4M | 1.1M |
| Debt Repayment | 149K | 161K | 176K | 191K | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||||||
| Net Debt | -43M | -19M | -16M | -22M | -26M | 4.2M | 4.6M | N/A | N/A | -79M |
| Cash & Equiv. | 39M | 20M | 13M | 8.5M | 31M | 791K | 437K | 11M | 5.2M | 79M |
| Long-Term Debt | 149K | 523K | 331K | 125K | 5.0M | 5.0M | 5.0M | N/A | N/A | N/A |
| Debt/Equity | N/A | 0.05 | 0.05 | 0.02 | 0.34 | 5.83 | -78.13 | 0.06 | 3.58 | 0.00 |
| Interest Coverage | -265.1 | -314.4 | -393.4 | -436.5 | -24.1 | -23.9 | 152.5 | 22.2 | -3622.0 | -3622.0 |
| Equity | N/A | 15M | 11M | 14M | 15M | 857K | -64K | 10.0M | 1.3M | 78M |
| Total Assets | 436K | 31M | 25M | 30M | 42M | 32M | 529K | 11M | 6.1M | 82M |
| Total Liabilities | N/A | 15M | 14M | 16M | 27M | 27M | 419K | 556K | 4.8M | 4.0M |
| Intangibles | N/A | 3.0M | 2.0M | 1.8M | 1.8M | 357K | 46K | N/A | N/A | N/A |
| Retained Earnings | N/A | -311M | -333M | -361M | -388M | -420M | -3.4M | -21M | -28M | -104M |
| Working Capital | N/A | 16M | 12M | 19M | 23M | 15M | 317K | 10M | 1.1M | 76M |
| Current Assets | N/A | 21M | 17M | 24M | 32M | 27M | 491K | 11M | 5.8M | 80M |
| Current Liabilities | N/A | 5.5M | 5.7M | 5.1M | 9.1M | 11M | 174K | 528K | 4.8M | 3.4M |
| Per Share Data | ||||||||||
| EPS | -191.25 | -153.75 | -112.50 | -74.25 | -45.75 | -39.75 | 3.00 | 22.38 | 1.16 | -0.27 |
| Owner EPS | -216.40 | -182.54 | -139.92 | -61.87 | -46.70 | -37.27 | -24.63 | 16.23 | 0.64 | -0.21 |
| Book Value | N/A | 94.29 | 56.57 | 36.44 | 25.88 | 1.04 | -0.34 | 37.22 | 0.22 | 1.15 |
| Cash Flow/Share | -174.66 | -149.34 | -116.35 | -51.78 | -40.36 | -33.21 | 4.09 | 18.09 | 0.88 | -0.19 |
| Dividends/Share | 0.00 | N/A | N/A | N/A | N/A | 0.00 | N/A | 0.00 | 0.00 | 0.00 |
| Shares Out. | 0.1M | 0.2M | 0.2M | 0.4M | 0.6M | 0.8M | 0.2M | 0.3M | 6.0M | 67.2M |
| Valuation | ||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -6.3 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | 182.6 | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 8.8 | 1.1 | 3.1 | 3.7 | N/A | N/A | N/A | N/A | 1.5 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | -18.6% | -196.5% | -45.6% | -50.5% | N/A | 1.7% | N/A | N/A | -11.4% |
| Market Cap | 0 | 137M | 11M | 44M | 55M | 0 | 44M | 0 | 0 | 115M |
| Avg. Price | 0.00 | 16,939.57 | 8,702.40 | 2,178.09 | 2,628.00 | 0.00 | 1,115.94 | 0.00 | 0.00 | 1.71 |
| Year-End Price | 0.00 | 17,982.00 | 1,296.00 | 2,462.40 | 2,073.60 | 0.00 | 745.20 | 0.00 | 0.00 | 1.71 |
Microbot Medical Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Microbot Medical Inc. (MBOT) has a return on equity (ROE) of 123.8%. This indicates the company generates strong returns for shareholders.
The Ledger Terminal provides 9 years of financial data for Microbot Medical Inc. (MBOT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Microbot Medical Inc. (MBOT) has a book value per share of $0.22, based on its most recent annual SEC filing.